hotspot -WSS

hotspot

author：knowledge 2025-10-01 15:31:10 - browse：98322

Pfizer plans to exit a major biotechnology industry trade association. Cindy Ord/Getty Images for Pfizer/BioNTech

WASHINGTON — Pfizer has decided to leave the Biotechnology Innovation Organization, according to two sources familiar with the planning.

The departure is a blow to BIO, which represents members ranging from small biotech startups to massive pharmaceutical companies. The group on Tuesday announced its new CEO, rare disease advocate and biotech executive John Crowley.

“The economic situation for the industry is difficult indeed and we of course are disappointed that any company would be forced to take a break from its BIO membership. We certainly hope that when economic conditions improve, we can welcome those companies back and welcome new members to join us as well, but it in no way affects our mission of protecting patients and medical innovation in the United States,” said BIO’s Chief Public Affairs and Marketing Officer Rich Masters. Masters said he wouldn’t comment on the status of any particular member.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： The problems with dementia villages

Wikipedia

WSS

FDA clears Verve to begin U.S. study of gene

Readout LOUD podcast: Live from the 2023 STAT Summit

Study on Amgen’s bispecific immunotherapy produces positive data

NIH director takes cautious approach to Biden drug pricing priority

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

The surgeon had a dilemma only a Nazi medical text could resolve

explore

hotspot

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

J&J lung cancer data amount to new salvo against AstraZeneca

Medical records are filled with copy

EU regulator recommends expanding Mounjaro approval to obesity

Sports medicine is finally prioritizing gender equality

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Virginia high school admissions case could be legal follow

Smaller biotechs seek to piggyback on weight loss drug boom

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Why doctors need education on FDA device approval process

hotspot

FDA clears AI tool for detecting skin cancer

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Prior authorization will have to move faster under new Biden rule

Prior authorization will have to move faster under new Biden rule

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

The tragedy of Johnson & Johnson’s Covid vaccine

Wikipedia

hotspot

focus

explore